Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01649869
Other study ID # 11-0069
Secondary ID HHSN272201100035
Status Completed
Phase Phase 2
First received
Last updated
Start date February 24, 2015
Est. completion date December 24, 2019

Study information

Verified date March 22, 2018
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an international, multi-center, double-blind, placebo-controlled evaluation valganciclovir treatment for up to 54 children (up to 4 years of age) with virologically-confirmed congenital CMV infection and hearing loss. Subject participation will be over a six-month period and study subjects will be stratified according to age. The primary objective is to assess whether a six-week course of oral valganciclovir can stabilize the hearing of children with congenital CMV infection who present with hearing loss.


Description:

Congenital cytomegalovirus (CMV) infection is the most frequent known viral cause of mental retardation, and is the leading non-genetic cause of sensorineural hearing loss in many countries including the United States. This is a Phase II international, multi-center, double-blind, placebo-controlled evaluation of 6 weeks of oral valganciclovir treatment or 6 weeks of placebo for fifty-four male and female infants/toddlers 1 month through 3 years of age (up to 4 years of age) with virologically-confirmed congenital CMV infection and hearing loss. Patient who are between 1 month and 4 years of age and who have SNHL (Sensorineural Hearing Loss) and are eligible for enrollment. The expected study duration is 3.5 years from enrollment of first study subject. The primary objective is to assess whether a six week course of oral valganciclovir can stabilize the hearing of children with congenital CMV infection who present with hearing loss. The secondary objective is to define the following responses as a function of systemic exposure to ganciclovir (active metabolite of valganciclovir): CMV viral load in blood; CMV viral load in urine; and CMV viral load in saliva. Also, to define the safety and tolerability of valganciclovir in enrolled subjects. The tertiary objective is to define the pharmacokinetics of ganciclovir (metabolite) following administration of valganciclovir (prodrug) in enrolled subjects.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date December 24, 2019
Est. primary completion date December 24, 2019
Accepts healthy volunteers No
Gender All
Age group 1 Month to 4 Years
Eligibility Inclusion Criteria: 1. Signed informed consent from parent(s) or legal guardian(s) 2. Sensorineural hearing loss (>/= 21dB in one or both ears, documented within 12 weeks prior to study entry) 3. Children from 1 month through 3 years of age (up to the 4th birthday) Exclusion Criteria: 1. Imminent demise 2. Profound sensorineural hearing loss (> 90dB) in both ears 3. Patients receiving other antiviral agents or immune globulin 4. Gastrointestinal abnormality which might preclude absorption of an oral medication (e.g., a history of necrotizing enterocolitis) 5. Documented renal insufficiency, as noted by a creatinine clearance < 10 mL/min/1.73m2 at time of study enrollment 6. Breastfeeding from mother who is receiving ganciclovir, valganciclovir, foscarnet, cidofovir, or maribavir 7. Infants known to be born to women who are HIV positive (but HIV testing is not required for study entry). 8. Current receipt of other investigational drugs 9. Previous receipt of ganciclovir or valganciclovir 10. Known hypersensitivity to ganciclovir, valganciclovir, or components of the product 11. Inability to attend follow-up hearing and clinical assessments 12. Infants with Auditory neuropathy/dyssynchrony. 13. Children with another known etiology for SNHL (e.g. connexin 26, syndrome or metabolic disorder associated with SNHL, inner ear malformation and widened vestibular aqueducts, meningitis). Exclusion of each of these conditions is not required for trial enrollment.

Study Design


Intervention

Other:
Placebo
Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
Drug:
Valganciclovir
Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.

Locations

Country Name City State
United Kingdom Birmingham Heartlands Hospital Birmingham
United Kingdom Bristol Royal Hospital for Children - Paediatric Immunology Bristol Bristol, City Of
United Kingdom Pennine Acute Hospitals NHS Trust, North Manchester General Hospital - Children's and Adolescent Services Crumpsall
United Kingdom John Radcliffe Hospital - Children's Hospital - Paediatric Infectious Disease and Immunology Headington, Oxford
United Kingdom Great Ormond Street Hospital - Infectious Diseases London London, City Of
United Kingdom Saint George's Hospital - Pediatric Infectious Diseases London London, City Of
United Kingdom The Great North Children's Hospital - Paediatric Immunology Newcastle Upon Tyne
United Kingdom Sheffield Children's Hospital - Immunology Sheffield
United Kingdom Southampton Children's Hospital - Allergy, Immunology and Infection Southampton, Hampshire
United States University of Alabama - Children's of Alabama - Clinical Virology Birmingham Alabama
United States Carolinas Medical Center - Pediatrics - Infectious Diseases Charlotte North Carolina
United States Nationwide Children's Hospital - Neonatology - Center for Perinatal Research Columbus Ohio
United States Texas Medical Center - Texas Children's Hospital Houston Texas
United States Steven and Alexandra Cohen Childrens Medical Center of New York - New Hyde Park - Infectious Disease Manhasset New York
United States Rhode Island Hospital - Pediatrics Providence Rhode Island
United States University of Rochester Medical Center - Golisano Children's Hospital - Infectious Diseases Rochester New York
United States Washington University School of Medicine in St. Louis - Center for Clinical Studies Saint Louis Missouri
United States Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. A single, independent study audiologist who is masked (blinded) to treatment assignment will assess the audiology test battery for each subject and assign the classifications of normal hearing, mild hearing loss, moderate hearing loss, or severe hearing loss based upon their hearing thresholds (in decibels). The classifications will be assigned by ear (one for the left ear and one for the right ear), giving "total ear" classifications. At the analyses stage, the "best ear" classification for the subject at that study visit will be determined; for example, if a subject had mild hearing loss in their left ear and severe hearing loss in their right ear, then the "best ear" classification will be mild hearing loss. Not both ears are evaluable for all subjects. In some subjects, only one ear is evaluable. Day 1 through Day 180
Secondary Number of Best Ear That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing [ex. Improved+ no Change (Normal to Normal) Versus Other]. A single, independent study audiologist who is masked (blinded) to treatment assignment will assess the audiology test battery for each subject and assign the classifications of normal hearing, mild hearing loss, moderate hearing loss, or severe hearing loss based upon their hearing thresholds (in decibels). The classifications will be assigned by ear (one for the left ear and one for the right ear), giving "total ear" classifications. At the analyses stage, the "best ear" classification for the subject at that study visit will be determined; for example, if a subject had mild hearing loss in their left ear and severe hearing loss in their right ear, then the "best ear" classification will be mild hearing loss. For this outcome, we combine the improved hearing and no change for the special case only of normal to normal. Other category include worsened and no change from (1) mild to mild hearing loss, (2) moderate to moderate hearing loss, or (3) severe to severe hearing loss. Day 1 through Day 180
Secondary Change in Best Ear Hearing Assessments [Improved Versus Other] Between Baseline and Study Month 6. A single, independent study audiologist who is masked (blinded) to treatment assignment will assess the audiology test battery for each subject and assign the classifications of normal hearing, mild hearing loss, moderate hearing loss, or severe hearing loss based upon their hearing thresholds (in decibels). The classifications will be assigned by ear (one for the left ear and one for the right ear), giving "total ear" classifications. At the analyses stage, the "best ear" classification for the subject at that study visit will be determined; for example, if a subject had mild hearing loss in their left ear and severe hearing loss in their right ear, then the "best ear" classification will be mild hearing loss. Day 1 through Day 180
Secondary Change in Best Ear Hearing Assessments [Worse + no Change (Abnormal to Abnormal) Versus Other] Between Baseline and Study Month 6. A single, independent study audiologist who is masked (blinded) to treatment assignment will assess the audiology test battery for each subject and assign the classifications of normal hearing, mild hearing loss, moderate hearing loss, or severe hearing loss based upon their hearing thresholds (in decibels). The classifications will be assigned by ear (one for the left ear and one for the right ear), giving "total ear" classifications. At the analyses stage, the "best ear" classification for the subject at that study visit will be determined; for example, if a subject had mild hearing loss in their left ear and severe hearing loss in their right ear, then the "best ear" classification will be mild hearing loss. Day 1 through Day 180
Secondary Change in Best Ear Hearing Assessments [Worse Versus Other] Between Baseline and Study Month 6. A single, independent study audiologist who is masked (blinded) to treatment assignment will assess the audiology test battery for each subject and assign the classifications of normal hearing, mild hearing loss, moderate hearing loss, or severe hearing loss based upon their hearing thresholds (in decibels). The classifications will be assigned by ear (one for the left ear and one for the right ear), giving "total ear" classifications. At the analyses stage, the "best ear" classification for the subject at that study visit will be determined; for example, if a subject had mild hearing loss in their left ear and severe hearing loss in their right ear, then the "best ear" classification will be mild hearing loss. Day 1 through Day 180
Secondary Change in Total Ear Hearing Assessments [Improved Versus Other] Between Baseline and Study Month 6. A single, independent study audiologist who is masked (blinded) to treatment assignment will assess the audiology test battery for each subject and assign the classifications of normal hearing, mild hearing loss, moderate hearing loss, or severe hearing loss based upon their hearing thresholds (in decibels). The classifications will be assigned by ear (one for the left ear and one for the right ear), giving "total ear" classifications. At the analyses stage, the "best ear" classification for the subject at that study visit will be determined; for example, if a subject had mild hearing loss in their left ear and severe hearing loss in their right ear, then the "best ear" classification will be mild hearing loss. Day 1 through Day 180
Secondary Change in Total Ear Hearing Assessments [Worse+ no Change (Abnormal to Abnormal) Versus Other] Between Baseline and Study Month 6. A single, independent study audiologist who is masked (blinded) to treatment assignment will assess the audiology test battery for each subject and assign the classifications of normal hearing, mild hearing loss, moderate hearing loss, or severe hearing loss based upon their hearing thresholds (in decibels). The classifications will be assigned by ear (one for the left ear and one for the right ear), giving "total ear" classifications. At the analyses stage, the "best ear" classification for the subject at that study visit will be determined; for example, if a subject had mild hearing loss in their left ear and severe hearing loss in their right ear, then the "best ear" classification will be mild hearing loss. Day 1 through Day 180
Secondary Change in Total Ear Hearing Assessments [Worse Versus Other] Between Baseline and Study Month 6. A single, independent study audiologist who is masked (blinded) to treatment assignment will assess the audiology test battery for each subject and assign the classifications of normal hearing, mild hearing loss, moderate hearing loss, or severe hearing loss based upon their hearing thresholds (in decibels). The classifications will be assigned by ear (one for the left ear and one for the right ear), giving "total ear" classifications. At the analyses stage, the "best ear" classification for the subject at that study visit will be determined; for example, if a subject had mild hearing loss in their left ear and severe hearing loss in their right ear, then the "best ear" classification will be mild hearing loss. Day 1 through Day 180
Secondary Association of Change in Viral Load (Blood) With Change in Total Ear Hearing at 6 Months Analysis of actual viral load was done using log base 10 transformation. Undetectable viral load value was replaced by a value of 10. A summary measure of the viral load over time considers all time points available by calculating the average area under the curve (AUC) (trapezoidal rule) applied to the log base 10 viral load. Average is based on the maximum period of time with viral load data for a given subject. The average or standardize AUC units is therefore the original AUC units of log 10 copies/ml*days divided by days in study which equals log 10 copies/ml. At 6 months
Secondary Association of Change in Viral Load (Saliva) With Change in Total Ear Hearing at 6 Months Analysis of actual viral load was done using log base 10 transformation. Undetectable viral load value was replaced by a value of 10. A summary measure of the viral load over time considers all time points available by calculating the average area under the curve (AUC) (trapezoidal rule) applied to the log base 10 viral load. Average is based on the maximum period of time with viral load data for a given subject. The average or standardize AUC units is therefore the original AUC units or log 10 copies/ml*days divided by days in study which equals log 10 copies/ml. At 6 months
Secondary Association of Change in Viral Load (Urine) With Change in Total Ear Hearing at 6 Months Analysis of actual viral load was done using log base 10 transformation. Undetectable viral load value was replaced by a value of 10. A summary measure of the viral load over time considers all time points available by calculating the average area under the curve (AUC) (trapezoidal rule) applied to the log base 10 viral load. Average is based on the maximum period of time with viral load data for a given subject. The average or standardize AUC units is therefore the original AUC units of log 10 copies/ml*days divided by days in study which equals log 10 copies/ml. At 6 months
Secondary Association of Change in Viral Load (Blood) With Change in Best Ear Hearing at 6 Months Analysis of actual viral load was done using log base 10 transformation. Undetectable viral load value was replaced by a value of 10. A summary measure of the viral load over time considers all time points available by calculating the average area under the curve (AUC) (trapezoidal rule) applied to the log base 10 viral load. Average is based on the maximum period of time with viral load data for a given subject. The average or standardize AUC units is therefore the original AUC units of log 10 copies/ml*days divided by days in study which equals log 10 copies/ml. At 6 months
Secondary Association of Change in Viral Load (Saliva) With Change in Best Ear Hearing at 6 Months Analysis of actual viral load was done using log base 10 transformation. Undetectable viral load value was replaced by a value of 10. A summary measure of the viral load over time considers all time points available by calculating the average area under the curve (AUC) (trapezoidal rule) applied to the log base 10 viral load. Average is based on the maximum period of time with viral load data for a given subject. The average or standardize AUC units is therefore the original AUC units of log 10 copies/ml*days divided by days in study which equals log 10 copies/ml. At 6 months
Secondary Association of Change in Viral Load (Urine) With Change in Best Ear Hearing at 6 Months Analysis of actual viral load was done using log base 10 transformation. Undetectable viral load value was replaced by a value of 10. A summary measure of the viral load over time considers all time points available by calculating the average area under the curve (AUC) (trapezoidal rule) applied to the log base 10 viral load. Average is based on the maximum period of time with viral load data for a given subject. The average or standardize AUC units is therefore the original AUC units of log 10 copies/ml*days divided by days in study which equals log 10 copies/ml. At 6 months
Secondary Detection of Viruria (Urine) by PCR Six Weeks After Trial Entry Each subject either has positive or negative PCR results. Virus is detected if the PCR is positive. At 6 weeks (Day 42)
Secondary Detection of Viruria (Urine) by PCR Six Month After Trial Entry Each subject either has positive or negative PCR results. Virus is detected if the PCR is positive. At 6 months
Secondary Detection of Viremia (Blood) by PCR Six Weeks After Trial Entry Each subject either has positive or negative PCR results. Virus is detected if the PCR is positive. At 6 weeks (Day 42)
Secondary Detection of Viremia (Blood) by PCR Six Month After Trial Entry Each subject either has positive or negative PCR results. Virus is detected if the PCR is positive. At 6 months
Secondary Detection of CMV in Saliva by PCR Six Weeks After Trial Entry Each subject either has positive or negative PCR results. Virus is detected if the PCR is positive. At 6 weeks (Day 42)
Secondary Detection of CMV in Saliva PCR Six Month After Trial Entry Each subject either has positive or negative PCR results. Virus is detected if the PCR is positive. At 6 months
Secondary The Quantitative Log Change in Viremia From Baseline to Month 6. The quantitative change (Month 6 minus baseline) in viremia (blood) Quantitative viral load by PCR in log 10 units measured in urine after 6 weeks of therapy; if undetectable, viral load is assigned a value of 10 (1 in log 10 units). Baseline to month 6
Secondary The Quantitative Log Reduction in Viruria Detected After 6 Weeks of Therapy The quantitative log reduction in viruria (urine) detected after 6 weeks of therapy. Quantitative viral load by PCR in log 10 units measured in urine after 6 weeks of therapy; if undetectable, viral load is assigned a value of 10 (1 in log 10 units) Baseline thru months 6
Secondary The Quantitative Log Reduction in CMV in Saliva Detected After 6 Weeks of Therapy The quantitative log reduction in CMV in saliva (urine) detected after 6 weeks of therapy. Quantitative viral load by PCR in log 10 units measured in urine after 6 weeks of therapy; if undetectable, viral load is assigned a value of 10 (1 in log 10 units) Baseline thru months 6
Secondary Number of Adverse Events in the Active Group That Resulted in Discontinuation of Valganciclovir AE resulting in discontinuation of valganciclovir (active group only). This outcome summarizes the number of adverse events (AEs) that resulted in the discontinuation of valganciclovir in the active group only. Day 1 thru day 70
Secondary Adverse Event (AE) Resulting in Unresolved Outcome Adverse event resulting in unresolved outcome. This outcome summarizes the number of adverse events (AEs) that resulted in unresolved outcome of that AE. Day 1 thru day 70
Secondary Adverse Event (AE) Resulting in Unanticipated Medically Attended Visit Adverse event resulting in unanticipated medically attended visit. This outcome summarizes the number of adverse events (AEs) that resulted in the unanticipated medically attended visit. Day 1 thru day 70
See also
  Status Clinical Trial Phase
Completed NCT00023036 - Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Terminated NCT01037712 - In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Phase 4
Completed NCT00370006 - Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT01552369 - CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Phase 4
Completed NCT00223925 - Maribavir for Prevention of CMV After Stem Cell Transplants Phase 2
Active, not recruiting NCT05085366 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Phase 3
Completed NCT01220895 - Alternate Donor Study of Pre-Emptive Cellular Therapy Phase 2
Completed NCT00942305 - Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients Phase 2
Completed NCT00373412 - Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge Phase 1
Completed NCT05105048 - A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 Phase 1
Completed NCT00386412 - TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant Phase 2
Completed NCT03382405 - Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults Phase 1
Completed NCT02454699 - Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers Phase 1
Active, not recruiting NCT03910478 - Dried Blood Spot Testing of CMV Detection in HCT Recipients N/A
Completed NCT01354301 - Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Phase 4
Active, not recruiting NCT01473849 - Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients N/A
Completed NCT00880789 - Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus Phase 1
Completed NCT00817908 - Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients N/A
Completed NCT00273143 - A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients. Phase 1